BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner

PURPOSE OF REVIEW: This review focuses on the feasibility of combining Bruton’s tyrosine kinase (BTK) inhibitors (BTKis) with chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). Potential scenarios for combination treatment with th...

Descripción completa

Detalles Bibliográficos
Autores principales: Munoz, Javier L., Wang, Yucai, Jain, Preetesh, Wang, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Lymphomas (T Hilal, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474429/
https://www.ncbi.nlm.nih.gov/pubmed/35596920
http://dx.doi.org/10.1007/s11912-022-01286-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474429/
https://www.ncbi.nlm.nih.gov/pubmed/35596920
http://dx.doi.org/10.1007/s11912-022-01286-0

Ejemplares similares